Company intelligence / Profile preview

Biotricity Inc.

Redwood City, California, United Statesbiotricity.com ↗

Ownership: Public · BTCY
Development stage: Commercial

Overview

Biotricity has received FDA clearance for its Bioflux device and software components, enabling the company to bring its remote cardiac monitoring solutions to the U.S. market. The company has experienced significant growth, with a 256.4% increase between 2020 and 2023, and has been recognized by the Financial Times as one of the fastest-growing companies in the Americas in 2025.

Therapeutic areas: Cardiovascular
Modalities: Remote monitoring devicesdiagnostic solutions
Industry: Physiological Monitoring

Partnerships

B-Secur (for integrated heart monitoring)

Financials

Market cap: $1.8M
Total revenue: $4.3M
Enterprise value: $28.3M

Beyond the preview

Go deeper on Biotricity Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biotricity Inc..

Explore the full profile